Equine-assisted Therapy for Therapy-resistant Adolescents With Autism Spectrum Disorders, a Replicated AB-design

NCT ID: NCT05200351

Last Updated: 2024-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-14

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the (cost)effectivity of Equine assisted Therapy in adolescents with Autism Spectrum disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has a mixed-methods strategy consisting of three elements: a randomized, multiple-baseline single-case design (n=35), a qualitative study (n=8-10) and a cost-effectiveness study (n=6). After obtaining written informed consent, participants will be randomly assigned to one of the five pre-defined baseline lengths (2-6 weeks) to increase the internal validity of the design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emotion Regulation Autism Spectrum Disorder Adolescent - Emotional Problem

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Participants will be randomly assigned to one of the five pre-defined baseline lengths (2-6 weeks) to increase the internal validity of the design with a 1:1 allocation using permuted blocks of random sizes.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EAT Intervention

15 sessions of EAT

Group Type EXPERIMENTAL

Equine assisted Therapy (EAT)

Intervention Type BEHAVIORAL

15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Equine assisted Therapy (EAT)

15 sessions of EAT will be given. Activities will be with or in the presence of the horse. There will be no horseriding.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* between 11-18 years old;
* a clinical diagnosis of autism spectrum disorders according the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5) as diagnosed by a Beroepen in de Individuele Gezondheidszorg (BIG) registered healthcare professional;
* insufficient emotion regulation after regular therapy for at least 1,5 years as indicated by a score above clinical cut-off (T-score = 65) on the EDI;
* comorbidities are allowed except for those interfering with safety.

Exclusion Criteria

* unable to respond to questions (parents or adolescents);
* no access to an Internet connection;
* insufficient mastery of Dutch language in parents or adolescents;
* physically incapable to work with the horses;
* unstable medication use;
* total intelligence quotient (IQ) equal to or below 80 on the Wechsler Intelligence Scale for Children (WISC-III-R or WISC-V);
* allergic or phobic to horses;
* insufficient regulation to safely handle the horses;
* therapy with horses within the last two years.
Minimum Eligible Age

11 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

Sponsor Role collaborator

Karakter Kinder- en Jeugdpsychiatrie

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nanda Lambregt-Rommelse, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Radboud/Karakter

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karakter

Ede, Gelderland, Netherlands

Site Status RECRUITING

Horses & Co

Heerjansdam, , Netherlands

Site Status RECRUITING

De Gagelhoeve

Mill, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jenny den Boer, Drs

Role: CONTACT

0031-318676611

Helen Klip, Dr.

Role: CONTACT

0031-243512222

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jenny den Boer, Drs

Role: primary

Esther van Noort

Role: primary

Anita Blonk, Dr.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Trzmiel T, Purandare B, Michalak M, Zasadzka E, Pawlaczyk M. Equine assisted activities and therapies in children with autism spectrum disorder: A systematic review and a meta-analysis. Complement Ther Med. 2019 Feb;42:104-113. doi: 10.1016/j.ctim.2018.11.004. Epub 2018 Nov 5.

Reference Type BACKGROUND
PMID: 30670226 (View on PubMed)

den Boer JC, Klip H, Blonk A, Lenselink M, Kaijdoe SPT, Tielkes M, van Zandbeek A, Bres G, Herinx M, Staal WG, Rommelse N. Study Protocol: Pegasus: psychotherapy incorporating horses for 'therapy-resistant' adolescents with autism spectrum disorders, a study with series of randomised, baseline controlled n-of-1 trials. BMC Psychiatry. 2024 Jul 10;24(1):499. doi: 10.1186/s12888-024-05879-w.

Reference Type DERIVED
PMID: 38987737 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

636310020

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

185-20 Pegasus

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Trial of CM-AT in Children With Autism
NCT00881452 COMPLETED PHASE3